AbbVie (ABBV) announced that it has entered into an agreement with the Trump administration aimed at expanding access and affordability for Americans while safeguarding and investing in U.S. pharmaceutical innovation.
As part of the agreement, AbbVie will provide lower prices within Medicaid and commit $100 billion over the next decade toward U.S.-based research, development, and capital investments, including manufacturing facilities. The company also plans to broaden its direct-to-patient offerings through TrumpRx, covering widely used medicines such as ALPHAGAN, COMBIGAN, HUMIRA, and SYNTHROID.
The agreement addresses all four of the President's drug pricing priorities. It was made possible by exemptions from tariffs and future price mandates, alongside the administration's continued efforts to ensure that global drug prices reflect the full value of U.S. medical innovation. Additional terms of the agreement remain confidential.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.